Shalabh Gupta

1 week ago | healio.com | Jill Rollet |Richard Smith |Shalabh Gupta

Key takeaways:Of survey respondents, 47% said large number and large size of pills were among top phosphate binder adherence barriers. An investigational agent is smaller, swallowed whole and dosed with fewer pills. BOSTON — Patients on kidney dialysis reported better adherence to an investigational phosphate-binding agent designed to be smaller, swallowed whole and dosed with fewer pills than available oral therapies, according to survey data.